SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is trending amidst a sharp pullback, primarily driven by increased CME margin requirements that triggered liquidations. A significant portion of the community views this as a buying opportunity, pointing to an impending China export ban, strong industrial demand from AI and EVs, and a perceived disparity between physical and paper silver prices. Conversely, many contend the recent surge was an unsustainable run, anticipating further volatility.

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

Aquestive Therapeutics is experiencing heightened investor conversation as the FDA's decision date for its Anaphylm oral film rapidly approaches, with widespread optimism for the needle-free, highly portable epinephrine treatment. Community discussions center on the product's "game-changing" convenience and the potential for a significant short squeeze, actively countering skepticism from bearish positions.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is trending due to impressive preliminary Phase 3 trial results showing an 80% reduction in breast cancer recurrence, alongside an extended insider lock-up signaling strong management confidence. This news has ignited intense community discussion about its low float, extremely high cost to borrow, and significant short interest, leading to widespread speculation of a substantial short squeeze and a potential multi-billion dollar valuation for its breast cancer therapy.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical (RARE) is trending due to significant market volatility after its bone disease drug, setrusumab, failed to meet primary endpoints in recent Phase 3 trials. The community is actively debating whether the ensuing sharp share price decline is an overreaction, pointing to the company's existing portfolio of approved therapies and robust pipeline. High trading volume reflects strong investor engagement as participants assess the company's revised valuation and potential for a rebound.

Sprott Physical Silver Trust - Units

Sprott Physical Silver Trust ET

PSLV is trending as community discussion focuses on a looming "silversqueeze" driven by accelerating industrial demand from sectors like AI and EVs, coupled with reported restrictions on silver exports from major producers. Investors are actively debating a growing global physical silver shortage and its potential for significantly higher prices, viewing physically-backed trusts like PSLV as a key play against market manipulation.

TryHard Holdings Ltd. is a lifestyle entertainment company that operates in Japan offering a diverse range of services across the entertainment and hospitality sectors. It operates through the following business segments: Consultancy and management, Event curation, Sub-leasing and Restaurants. The Consultancy and management segment provides expert services to clubs, including operations, event management, and strategic support to enhance performance and engagement. The Event curation segment organize and produce own events, also provides a full suite of services, including event planning, construction, entertainment booking, event operation, and ticket sales. The Sub-Leasing segment acts as an intermediary between landlords and clubs. The Restaurants segment operates several restaurants. The company was founded on October 16, 2013 and is headquartered in Osaka, Japan.

TryHard Holdings Ltd.

TryHard Holdings Ltd. (THH) is trending due to its recent NASDAQ IPO as a Japanese lifestyle entertainment company, sparking highly speculative trading and extreme volatility. The community is sharply divided, with some anticipating a significant short squeeze given its low float and reported high ROE, while others actively label it a pump-and-dump scheme often promoted in social media groups. This clash of sentiment is driving intense discussion and rapid price movements.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending following its pivotal FDA approval of YARTEMLEA, marking its first commercial product and the only approved therapy for transplant-associated thrombotic microangiopathy (TA-TMA). Community sentiment is highly bullish, anticipating significant long-term value and a potential short squeeze, fueled by the immediate January 2nd launch and a strong financial position from its Novo Nordisk partnership. Investors are keenly awaiting further details, including pricing and commercial strategy, expected from the upcoming conference call.

BTQ Technologies Corp. engages in the business of post-quantum encryption. It focuses on applications to the blockchain industry. Its products include PQScale, Keelug, Kenting, Preon, QPoW, and QByte. The company was founded by Nicolas Roussy Newton on March 26, 2021 and is headquartered in Vancouver, Canada.

BTQ Technologies Corp

BTQ Technologies is generating significant conversation following the launch of its GPU-accelerated quantum emulator, QLEO, now compatible with NVIDIA CUDA-Q, which the community sees as a crucial step for adoption. Many investors are also highlighting recent insider buying by the CEO, emphasizing BTQ's potential to provide quantum-secure infrastructure for digital assets like Bitcoin and stablecoins. Despite current market volatility and pre-revenue status, the focus is on the long-term opportunity as the company positions itself to address emerging quantum threats.

NorthWestern Energy Group, Inc. engages in the provision of electricity and natural gas to customers in Montana, South Dakota, Nebraska, and Yellowstone National Park. It operates through the following segments: Electric, Natural Gas, and Other. The Electric segment is involved in the regulated electric utility business primarily providing generation, transmission, and distribution services to customers in the Montana and South Dakota jurisdictions. The Natural Gas segment focuses on the natural gas utility business primarily providing production, storage, transmission, and distribution services to customers in the Montana, South Dakota, and Nebraska jurisdictions. The company was founded in November 1923 and is headquartered in Sioux Falls, SD.

NorthWestern Energy Group Inc

Northwestern Corp.

Northwestern Corporation is trending due to recent favorable regulatory developments, including settlement agreements in Montana that are poised to increase electric and natural gas revenues. This positive fundamental news is driving significant community discussion, with multiple 'actionable trade alerts' circulating, highlighting bullish technical indicators and momentum. The broader context of NWE as a stable utility, offering dividend appeal and potential benefits from evolving energy policies, further fuels investor interest.

ImageneBio, Inc. is a clinical-stage biotechnology company that boldly imagines a world where patients can be free from the burden of grievous immunological/autoimmune and inflammatory (I&I) diseases. It focuses on the development of new medicines with differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The company was founded in February 2016, and is headquartered in San Diego, CA.

ImageneBio Inc.

ImageneBio, Inc.

ImageneBio (IMA) is trending due to highly divergent analyst ratings, with some initiating bullish coverage citing deep pipeline value and significant cash, while others warn of a long timeline to data and a lower valuation. The community is actively debating the company's substantial cash reserves and the long-term potential of its Phase 2b program for atopic dermatitis against the lack of near-term catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

A Comcast Corp. (CMCSA) analyst reduced the price target for the stock following the media and technology company’s quarterly results but retail sentiment was upbeat.Goldman Sachs analysts reduced the price target for&nbsp;<a href="https://stocktwits.com/symbol/CMCSA">Comcast stock</a> to $44 from $50 and maintained a ‘Buy’ rating. The updated price target suggests roughly 32% upside potential.The firm noted that the fourth-quarter domestic broadband missed expectations due to a weaker-than-expected December.&nbsp;The brokerage also said that Comcast management is now more aggressively using wireless as a tool to drive subscriber acquisition and retention. Therefore, it expects near-term headwinds stemming from elevated direct product costs.As such, the firm lowered the 2025 broadband average revenue per user growth estimate to 3% from 3.4% due to Comcast’s strategic shift to emphasize converged product bundles aimed at its high-end consumer price.Philadelphia, Pennsylvania-based Comcast reported Thursday before the market opened fiscal year 2024 fourth-quarter adjusted earnings per share (EPS) of $0.96 and revenue of $31.92 billion, up 2.1% year-over-year (YoY). Both metrics exceeded expectations.The stock fell 11% on Thursday as total domestic broadband customers fell by 139,000 YoY in the fourth quarter, and the Peacock streaming business’ subscriber count, at 36 million, was flat with the previous quarter.&nbsp;On Stocktwits, sentiment toward Comcast stock stayed ‘bullish’ (59/100) but message volume tempered to ‘normal’ levels.&nbsp;<figure class="image"><img style="aspect-ratio:637/135;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/cmcas_sentiment_3744eff603.png" alt="cmcas-sentiment.png" width="637" height="135"><figcaption>CMCSA sentiment and message volume January 30, as of 11:31 pm ET | Source:&nbsp;Stocktwits</figcaption></figure>A retail watcher on the platform called Thursday’s post-earnings sell-off a “historical” buying opportunity.<stembedurl>https://stocktwits.com/Josephmrp1/message/602246745</stembedurl>Another lamented the stock price decline despite the strong quarterly performance, the $15 billion stock buyback and the opening of the Epic Universe in the summer.<stembedurl>https://stocktwits.com/ElonMusk101/message/602242169</stembedurl>A third user predicted $40+ level for the stock in three months.<stembedurl>https://stocktwits.com/Xanderlg/message/602221326</stembedurl>Comcast stock has lost nearly 11% this year on top of 12% drop in 2024.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/atlassian-reports-beat-and-raise-2025-q2/chbMfcjRqL">Atlassian Stock Climbs To 3-Year High After-Hours On Beat-And-Raise Q2 But Retail Sentiment Lags</a>

 In this photo illustration, the Comcast Corporation logo is seen displayed on a smartphone screen next to a laptop keyboard.

Comcast Stock Snags Price Target Cut Following 11% Decline On Q4 Results But Retail Sees ‘Historical’ Buying Opportunity

Goldman analysts see near-term headwinds stemming from elevated product coasts as Comcast management aggressively uses wireless to drive subscriber acquisition and retention.

Equity

Goldman analysts see near-term headwinds stemming from elevated product coasts as Comcast management aggressively uses wireless to drive subscriber acquisition and retention.


DFLV
Dimensional ETF Trust - Dimensional US Large Cap Value ETF

Feed

News

Sentiment

Fundamentals

Info

Latest DFLV News

DFLVDimensional ETF Trust - Dimensional US Large Cap Value ETF